Section 29(5) is an additional, not exclusive, ground for infringement, and its non-applicability did not oust Sections 29(1) to (4).
Introduction:
In the fiercely competitive landscape of pharmaceuticals, where brand identity can be a lifeline for both companies and consumers, the clash between Mankind Pharma Limited and Novakind Bio Sciences Private Limited emerges as a riveting tale of trademark law, deceptive similarity, and judicial interpretation. Decided on August 7, 2023, by the High Court of Delhi, this case pits a pharmaceutical giant against a smaller player, unraveling the complexities of protecting a “family of marks” and the boundaries of corporate naming rights under India’s Trade Marks Act, 1999. With the plaintiff wielding its well-established “KIND” suffix against the defendant’s “NOVAKIND” branding, the court’s ruling offers a profound exploration of infringement, public safety, and the delicate balance between statutory compliance and intellectual property rights. This case study delves into the intricacies of the dispute, tracing its factual roots, procedural twists, legal arguments, and the judiciary’s nuanced reasoning, culminating in a decision that reinforces the sanctity of trademarks in the medicinal domain.
Detailed Factual Background:
Mankind Pharma Limited, the plaintiff, stands as India’s fifth-largest pharmaceutical company, a titan in the industry with a legacy dating back to 1986 when its founder, Ramesh Chand Juneja, adopted the trademark “MANKIND” as its trading style. Renowned for its extensive portfolio, the company boasts 268 brands ranked among the top five in their respective pharmaceutical categories, with 85 at the pinnacle and 67 in second place. Mankind has meticulously cultivated a “KIND family of marks,” incorporating “KIND” as a suffix in various product names, a branding strategy that has become a hallmark of its identity. The company holds registrations for the “MANKIND” mark across all classes and operates a plethora of websites, including mankindpharma.com, mankindmanforce.com, and vetmankind.com, underscoring its pervasive market presence.
The defendant, Novakind Bio Sciences Private Limited, entered the pharmaceutical fray with a corporate name and product branding that sparked Mankind’s ire. Novakind manufactures and sells medicinal preparations, notably Deflazacort tablets under the brand “DEFZAKIND,” prominently featuring “NOVAKIND BIO SCIENCES PRIVATE LIMITED” on its packaging with a registered trademark symbol (®). Mankind perceived this as an encroachment on its “KIND” family, arguing that “NOVAKIND” phonetically and structurally mimicked “MANKIND,” potentially confusing consumers and diluting its goodwill. On August 25, 2020, Mankind issued a cease-and-desist notice, demanding that Novakind abandon its use of “NOVAKIND” and “DEFZAKIND,” claiming infringement of its registered trademark. Novakind’s refusal to comply precipitated this legal showdown.
The crux of the dispute lies in the similarity between “MANKIND” and “NOVAKIND,” compounded by the shared “KIND” suffix, and Novakind’s bold display of its corporate name on product strips, which Mankind argued functioned as a trademark rather than a mere identifier. The stakes were high, given the pharmaceutical context where confusion could endanger public health, a factor that loomed large in the court’s considerations.
Detailed Procedural Background:
The legal saga began with Mankind Pharma filing CS(COMM) 188/2021 before the High Court of Delhi, seeking a permanent injunction to restrain Novakind from using “KIND” as part of its trade name or trademark for any pharmaceutical products. Concurrently, Mankind moved I.A. 5700/2021 under Order XXXIX Rules 1 and 2 of the Code of Civil Procedure (CPC), 1908, requesting an interim injunction. On April 20, 2021, the court granted an ex parte ad interim injunction, barring Novakind from manufacturing, marketing, or selling any pharmaceutical product bearing the “KIND” suffix or otherwise infringing Mankind’s registered trademark. This order remained in effect, casting a shadow over Novakind’s operations.Unwilling to acquiesce, Novakind countered with I.A. 3248/2023 under Order XXXIX Rule 4 CPC, seeking to vacate the interim injunction. Both parties completed their pleadings, submitting detailed arguments and evidence, including product packaging and statutory references.
Issues Involved in the Case:
The case presented a tapestry of legal and factual questions demanding resolution. Foremost was whether Novakind’s use of “NOVAKIND BIO SCIENCES PRIVATE LIMITED” and “DEFZAKIND” infringed Mankind’s registered “MANKIND” trademark under the Trade Marks Act, 1999, particularly given the shared “KIND” suffix? A pivotal issue was whether “NOVAKIND” functioned as a trademark or merely a corporate name, impacting the applicability of infringement provisions under Sections 29(2)(b) versus 29(5)? The court had to reconcile conflicting judicial precedents on the scope of Section 29(5) versus Sections 29(1) to (4), determining the legal framework for assessing infringement by corporate name usage.
Detailed Submission of Parties:
Mankind Pharma anchored its case on trademark infringement and public interest. Sibal argued that “MANKIND” and its “KIND” family of marks were deeply entrenched in the market, with registrations across all classes and a reputation synonymous with quality pharmaceuticals. He contended that “NOVAKIND” was deceptively similar to “MANKIND,” phonetically and structurally, risking consumer confusion, particularly given the “KIND” suffix’s prominence in Mankind’s branding. Pointing to the “DEFZAKIND” strip, plaintiff highlighted Novakind’s use of “NOVAKIND BIO SCIENCES PRIVATE LIMITED” in bold letters with a registered trademark symbol, asserting it functioned as a source identifier, not just a corporate name, thus falling under Section 29(2)(b). Plaintiff cited Novakind’s own admissions in its application—acknowledging recognition by doctors and intent to build reputation under “NOVAKIND”—to rebut claims of mere corporate use. Sibal challenged the Bombay High Court’s Cipla ruling, relying on Delhi High Court precedents like Bloomberg and Novartis to argue that Sections 29(1) to (4) remained applicable even if Section 29(5) did not fit. Emphasizing the pharmaceutical context, he invoked Supreme Court dicta from Cadila Health Care, stressing the heightened risk of confusion in medicinal products and the need for strict protection.
Novakind, through mounted a multi-pronged defense. Mahapatra argued that Mankind lacked standalone registration for “KIND,” precluding exclusivity over the suffix, and that “NOVAKIND” was a corporate name, not a trademark, used in compliance with the Drugs and Cosmetics Act’s labeling mandates. He leaned heavily on Section 29(5), asserting it exclusively governed infringement by corporate name usage, and since “MANKIND” and “NOVAKIND” were not identical, no violation occurred. Citing the Bombay High Court’s Cipla Full Bench decision, he contended that Sections 29(1) to (4) were inapplicable. Mahapatra further posited that pharmaceutical products, prescribed by trained professionals, minimized confusion risks, and that drugs were sold by brand names like “DEFZAKIND,” not manufacturer names, diluting any association with Mankind. He dismissed public health concerns, arguing that doctors and pharmacists’ expertise negated deception, and urged the court to vacate the injunction based on statutory necessity and lack of trademark use.
Detailed Discussion on Judgments Cited by Parties and Their Context:
The parties wielded an arsenal of judicial precedents, each illuminating distinct facets of trademark law. Mankind relied on Amritdhara Pharmacy v. Satya Deo Gupta (AIR 1963 SC 449), where the Supreme Court deemed “AMRITDHARA” and “LAKSHMANDHARA” confusingly similar for medicinal products, emphasizing phonetic and structural likeness from a consumer’s perspective. This bolstered Mankind’s claim of deceptive similarity between “MANKIND” and “NOVAKIND.” Mankind Pharma Ltd v. Cadila Pharmaceuticals Ltd ((2015) 61 PTC 465) from the Delhi High Court reinforced this, enjoining “METROKIND” due to the “KIND” suffix’s dominance in Mankind’s marks, affirming its source-identifying role. Bloomberg Finance LP v. Prafull Saklecha ((2014) 207 DLT 35) and Novartis AG v. Novaegis (India) Private Limited (MANU/DE/1012/2023), both Delhi High Court rulings, countered the Cipla view, holding that Section 29(5) did not preclude Sections 29(1) to (4), allowing broader infringement analysis when a mark doubles as a corporate name. Cadila Health Care Ltd v. Cadila Pharmaceuticals Ltd ((2001) 5 SCC 73) underscored the Supreme Court’s stance on heightened scrutiny for medicinal trademarks, rejecting the notion that professional dispensing eliminated confusion risks.
Novakind invoked Cipla Ltd v. Cipla Industries Pvt Ltd (AIR 2017 Bom 75), a Bombay High Court Full Bench decision, asserting that Section 29(5) alone applied to corporate name usage, requiring identity of marks, not mere similarity, thus favoring Novakind’s non-identical “NOVAKIND.” Dhiren Krishna Paul v. Health and Glow Retailing Pvt Ltd (2013 (53) PTC 355 (Mad)) and Chronicle Publications (P) Ltd v. Chronicle Academy Pvt Ltd (2010 (44) PTC 78 (Del)) echoed this, limiting infringement claims absent identical corporate name use in the same trade. These cases aimed to narrow the legal lens to Section 29(5), shielding Novakind from broader infringement claims.
Detailed Reasoning and Analysis of Judge:
The court's reasoning wove a meticulous tapestry of statutory interpretation, factual analysis, and public policy. The began by affirming Mankind’s robust trademark rights in “MANKIND,” registered across all classes, and its “KIND” family’s market recognition. Comparing “MANKIND” and “NOVAKIND,” he found them phonetically and structurally similar, with the shared “KIND” suffix heightening confusion risks, especially in pharmaceuticals where “KIND” was not generic. Drawing from Amritdhara and Cadila Pharmaceuticals (from Mankind v. Cadila), he held that such similarity satisfied Section 29(2)(b)’s test of deceptive similarity and likelihood of association for identical goods.
Addressing Novakind’s Section 29(5) defense, the judge grappled with the Cipla precedent but sided with Delhi High Court’s Bloomberg and Novartis rulings. The Court reasoned that Section 29(5) was an additional, not exclusive, ground for infringement, and its non-applicability did not oust Sections 29(1) to (4). Examining the “DEFZAKIND” strip, he noted “NOVAKIND BIO SCIENCES PRIVATE LIMITED”’s prominent display with a registered trademark symbol, concluding it functioned as a trademark under Section 2(zb), not merely a corporate name. This factual distinction from Cipla—where the mark was solely a corporate identifier—rendered Section 29(2)(b) applicable, as Novakind used “NOVAKIND” in trade to indicate source.
The Court dismissed Novakind’s ancillary arguments. The Drugs and Cosmetics Act’s naming requirement, he held, did not license infringing names; Novakind could adopt a non-conflicting identity. The contention that professional dispensing negated confusion was rebutted by Cadila Health Care’s insistence on a higher standard for medicinal marks, given human fallibility and prescription errors. He emphasized the consumer’s perspective—a person of average intelligence and imperfect recollection—over professional expertise, noting the real-world reliance on manufacturer names in India’s diverse healthcare landscape. Citing extensive U.S. and Indian precedents, he underscored the dire public health implications of medicinal confusion, refusing to speculate on its improbability.
Final Decision:
The court made the ad interim injunction of April 20, 2021, absolute, restraining Novakind from using “KIND” in its trade name or trademarks pending the suit’s disposal.
Law Settled in This Case:
The judgment clarified that Section 29(5) does not monopolize infringement analysis for corporate name usage; Sections 29(1) to (4) remain viable if the mark serves as a trademark. It affirmed that phonetic and structural similarity, especially in pharmaceuticals, suffices for infringement under Section 29(2)(b) when goods are identical and confusion or association is likely. The ruling entrenched a heightened duty of care for medicinal trademarks, prioritizing public safety over professional safeguards, and held that statutory naming obligations do not excuse infringement.
Case Title: Mankind Pharma Limited Vs Novakind Bio Sciences Private Limited
Date of Order: August 7, 2023
Case No.: CS(COMM) 188/2021
Neutral Citation: 2023:DHC:5653
Name of Court: High Court of Delhi
Name of Judge: Hon'ble Justice Shri C. Hari Shankar
Disclaimer: The information shared here is intended to serve the public interest by offering insights and perspectives. However, readers are advised to exercise their own discretion when interpreting and applying this information. The content herein is subjective and may contain errors in perception, interpretation, and presentation.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
